|
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China |
|
|
|
Titel: |
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China |
Auteur: |
Xiong, Anwen Wang, Lei Chen, Jianhua Wu, Lin Liu, Baogang Yao, Jun Zhong, Hua Li, Jie Cheng, Ying Sun, Yulan Ge, Hui Yao, Jifang Shi, Qin Zhou, Ming Chen, Bolin Han, Zhengxiang Wang, Jinliang Bu, Qing Zhao, Yanqiu Chen, Junqiang Nie, Ligong Li, Gaofeng Li, Xingya Yu, Xinmin Ji, Yinghua Sun, Daqiang Ai, Xiaohong Chu, Qian Lin, Yu Hao, Jiqing Huang, Dingzhi Zhou, Chengzhi Shan, Jinlu Yang, Hongzhong Liu, Xuewen Wang, Jing Shang, Yanhong Mei, Xiaodong Yang, Jie Lu, Dongmei Hu, Mingxiu Wang, Zhongmin Maxwell Li, Baiyong Xia, Michelle Zhou, Caicun |
Verschenen in: |
Lancet |
Paginering: |
Jaargang 405 () nr. 10481 pagina's 839-849 |
Jaar: |
2025 |
Inhoud: |
|
Uitgever: |
Elsevier Ltd |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|